Medicare's $50 GLP-1 pilot program excludes patients who have FDA-approved conditions for the drugs

The Medicare GLP-1 Bridge program was designed to fill a long-standing gap in federal coverage: a legal bar has historically prevented Medicare from covering drugs prescribed solely for weight loss. CMS spokesperson Timothy Foster said most prior authorization requests under the pilot have been completed in under 12 hours, and the program's initial weeks have allowed thousands of eligible beneficiaries to access the drugs at pharmacies nationwide.

But a structural feature of the program is leaving out patients who have both obesity and a separate condition that the FDA has already approved GLP-1s to treat. Under the program's rules, the $50 monthly price applies only to people using the drug solely for weight loss. Patients with diagnoses such as Type 2 diabetes or moderate to severe obstructive sleep apnea are instead redirected to their Medicare Part D plan, which does not carry the same discount.

Jeff La Marca, a 68-year-old New Jersey man with a BMI of 42, severe obstructive sleep apnea, a history of quadruple bypass surgery, and prediabetes, said his application to the Bridge program was denied. His GLP-1 prescription — for Zepbound, which carries a retail price of about $750 a month — remains unfilled. "This is now my quest, because it's my only chance to improve my health," he told NPR/KFF Health News.